In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
|Articles|June 1, 2000
Oncology NEWS International
- Oncology NEWS International Vol 9 No 6
- Volume 9
- Issue 6
Book Prepares Children for BMT Procedures
A new book, Me and My Marrow: A Kid’s Guide to Bone Marrow Transplants, helps guide children with cancer through the transplant procedure. The book was inspired by 13-year-old Christina Cuzzone, of Northbrook, Illinois, who was diagnosed with leukemia at age 9 and underwent a BMT. After recovering from the transplant, Christina recognized the need for a book to help other children.
Advertisement
A new book, Me and My Marrow: A Kids Guide to Bone Marrow Transplants, helps guide children with cancer through the transplant procedure. The book was inspired by 13-year-old Christina Cuzzone, of Northbrook, Illinois, who was diagnosed with leukemia at age 9 and underwent a BMT. After recovering from the transplant, Christina recognized the need for a book to help other children.
She shared her story with a neighbor employed by Fujisawa Healthcare, Inc., a local pharmaceutical company, and the company worked with her to create the book. It is being distributed to transplant centers nationwide and on the Internet at
Articles in this issue
over 26 years ago
Genentech Issues Warning on Herceptinover 26 years ago
How Physicians Can Effect Changes in Health Care Policyover 26 years ago
Four From Congress Receive Tsongas Awardover 26 years ago
NCI Targets Cancer Disparities With Community-Based Programsover 26 years ago
Mapping Predicts Nodal Status in Colorectal Cancer Patientsover 26 years ago
SSO President Tells Members: ‘Remember Your Core Values’over 26 years ago
HHS Grants $794 Million in Ryan White Funds to Improve HIV Servicesover 26 years ago
Rapid Dose Titration With Controlled-Release Oxycodoneover 26 years ago
Standard-Dose Chemo May Have Long-Term Cognitive EffectsAdvertisement
Related to this article
Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.
Experts preview ASTRO 2026 presentations to watch, including those on SOFT Preop, PSMAgRT, radiosurgery for depression, and AI tools for patient safety.
Data from the phase 3 MK-3475A-D77 trial support the Japanese approval of subcutaneous pembrolizumab and berahyaluronidase alfa.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Xiuning Le, MD, PhD, weighs sevabertinib against zongertinib and trastuzumab deruxtecan in HER2-mutant non–small cell lung cancer.
A prospective, multicenter study found that a blood-based miRNA assay combined with CA19-9 improved early detection of pancreatic ductal adenocarcinoma.
Final 5-year IMCgp100-202 data show tebentafusp improved OS vs investigator’s choice in untreated HLA-A*02:01–positive metastatic uveal melanoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Lutetium Lu 177 Dotatate Biosimilar Earns Final FDA Approval in GEP-NETs
2
PANXEON Liquid Biopsy Demonstrates Potential for Detecting Early Pancreatic Cancer
3
Rusfertide Earns Category 1 NCCN Recommendation in Polycythemia Vera
4
AdenoVerse Platform Receives FDA Designation for HPV-Associated Cancers
5